This Biotech Stock Could Be A Good “Bad News Buy”

When it comes to the biotech stock that’s the focus of today’s article, which plummeted in mid-October when the company abruptly pulled the plug on a critical Phase 2 trial due to safety concerns with the drug being studied, the author says the following: “We view the drop in the shares as an overreaction, and it has created an excellent buying opportunity. At current levels the stock has minimum downside risk, while its upside is unlikely to be affected by the disappointment.” For the stock in question that could be a good “bad news buy”, CLICK HERE.